Drug intelligence / Profile preview

atg7 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral, Intralesional, Parenteral
01

Overview

atg7 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Autophagy Related 7 (ATG7) gene. ATG7 is a critical E1-like enzyme in the autophagy pathway, essential for the conjugation of ATG12 to ATG5 and the lipidation of LC3, which are necessary steps for autophagosome formation. By inhibiting ATG7, this siRNA blocks autophagic flux, a process often exploited by cancer cells to survive metabolic stress and chemotherapy. In preclinical research, ATG7 siRNA is used to sensitize various tumors (such as pancreatic, breast, and cervical cancers) to treatment and to study the role of autophagy in metabolic and inflammatory diseases like diabetes and sepsis. It is typically delivered using specialized vehicles like lipid nanoparticles or micellar systems to enhance stability and cellular uptake.

Other names
ATG7 small interfering RNAATG-7 small interfering RNAATG 7 small interfering RNAautophagy-related 7 siRNAautophagy-related7 siRNAautophagy-related-7 siRNA
02

Targets

ATG7 (Ubiquitin-like modifier-activating enzyme ATG7)

Beyond the preview

Go deeper on atg7 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atg7 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call